AstraZeneca (AZ) has begun the second quarter on the front foot with a filing for a potential first-in-class cancer drug in the US, and an application to expand the use of its ovarian cancer drug ...
The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...
The pharmaceutical industry is poised for an opportunity to tweak parts of the Medicare drug pricing negotiation law, after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback